Printer Friendly

qmed REPORTS A 36 PERCENT INCREASE IN SECOND QUARTER SALES

 LAURENCE HARBOR, N.J., July 13 /PRNewswire/ -- qmed, Inc. (NASDAQ: QEKG) reported today a 36 percent increase in net sales of $2,655,454 for the second quarter ending May 31, 1993 vs. $1,950,860 during the corresponding period of last year. Net sales for the six months ending May 31, 1993, rose by 19 percent to $4,743,806 compared to net sales of $3,971,926 for the six months ending May 31, 1992. The company had a net profit of $15,481 for the quarter ending May 31, 1993 vs. net loss of $219,854 in the corresponding period of last year.
 Michael W. Cox. CEO of qmed, commented "Our sales increases are particularly impressive considering that large numbers of physicians still remain uncertain regarding how health care reform will impact their practice." Cox went on to say, "Our sales force's ability to increase our sales of cardiac, diabetic and vascular diagnostic technology to the primary care physician reinforces that the company's strategy is on track. In support of that strategy we are currently increasing the size of our sales force so that we can meet anticipated demand for our products once the health care package is completed." Cox continued to say, "Let me emphasize that we believe that the concept of developing and selling medical devices that assist the primary care physicians' `gate-keeping' role in providing cost effective health care, without compromising quality, is exactly what the Doctor and Washington have ordered."
 Cox said, "The long awaited results of the Diabetes Control and Complications Trial (DCCT) released on June 13, a $150 million funded NIH study, illuminating the lifesaving benefits of tight glucose control, demonstrated a 60 percent reduction in the risk of developing diabetic nerve damage. The methods to study and analyze improvement in nerve damage included the specific procedures which are incorporated in our patent pending nDx system." Cox continued, "Management expects the DCCT results to boost the sales of qmed's nDx technology."
 According to the company, nDx sales were up 21 percent in the second quarter.
 qmed, INC.
 Periods ended Three Months Six Months
 May 31 1993 1992 1993 1992
 Net sales $2,665,454 $1,950,860 $4,743,806 $3,971,926
 Net income 15,481 (219,854) (303,262) (217,104)
 Average shares 7,730,415 7,433,662 7,709,870 7,039,156
 Income (loss) per share $.00 ($.03) ($.04) ($.03)
 -0- 7/13/93
 /CONTACT: Debra Fenton of qmed, 908-566-2666/
 (QEKG)


CO: qmed, Inc. ST: New Jersey IN: MTC SU: ERN

PS-TS -- NY012 -- 0722 07/13/93 08:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 13, 1993
Words:434
Previous Article:NETWORK FINANCIAL SERVICES REACHES DEFINITIVE AGREEMENT TO ACQUIRE WESTMARK MORTGAGE
Next Article:CHILD CARE AWARE HELPING STRESSED-OUT PARENTS FIND QUALITY CHILD CARE AS NEW SCHOOL YEAR APPROACHES
Topics:


Related Articles
QUEST MEDICAL, INC. (NASDAQ) SECOND QUARTER OPERATING EARNINGS ADVANCE 78 PERCENT ON 43 PERCENT REVENUE GAIN
QMED REPORTS A 46 PERCENT INCREASE IN NET SALES IN THE THIRD QUARTER
QMED REPORTS A 3.3 PERCENT RISE IN FIRST QUARTER SALES
QMED REPORTS PROFITABLE THIRD QUARTER
QMED REPORTS A 41% REDUCTION IN FIRST QUARTER LOSS, COMPARED TO PRIOR YEAR
qmed REPORTS FOURTH QUARTER AND YEAR END RESULTS
QMED REPORTS THIRD QUARTER RESULTS
QMED REPORTS SECOND QUARTER RESULTS
qmed Reports Second Quarter Results
Qmed, Inc. Announces 1st Quarter Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters